Abstract: Coronary computed tomography angiography (CTA) has been increasingly used to detect coronary artery disease. The diagnostic performance of coronary CTA is well established with a high sensitivity and negative predictive value. Nevertheless, the diagnostic value of coronary CTA is offset by a high false positive rate, partly due to the technique lacking physio logical lesion assessment when performed in the conventional way. This has raised concerns regarding unnecessary invasive coronary angiography referrals and inappropriate revasculariza tion procedures. Recent advances in computational fluid dynamics and imagebased modeling have enabled the calculation of coronary artery blood flow and pressure under various modeled physiologic conditions from coronary CTA without the need for hyperemiainducing medica tions, modification of acquisition protocol or further radiation. Coronary flow and pressure can be derived both at rest and during simulated maximum hyperemia allowing for the calculation of fractional flow reserve from coronary CTA (FFR CTA ) across stenotic lesions in a fashion similar to invasive FFR. This novel noninvasive technology offers concurrent anatomical and functional assessment of major epicardial coronary arteries. The diagnostic performance of FFR CTA has been tested in three major trials where it resulted in accurate identification of ischemiarelated lesions. Similar to an invasive FFRguided management strategy, the use of FFR CTA has been shown to improve patients' outcomes and reduce health care costs. FFR CTA is emerging as an attractive alternative to invasive FFR. There are, however, several challenges that need to be overcome before FFR CTA can be incorporated into routine clinical practice.
Introduction
Coronary artery disease (CAD) is a worldwide leading cause of mortality and mor bidity. 1 It is estimated that more than half of cardiovascular deaths are classified as sudden cardiac death, usually as a result of acute myocardial infarction in patients with underlying atherosclerotic CAD. 2 Invasive coronary angiography (ICA) utilizing intra coronary injection of radiopaque contrast to obtain radiographic luminograms of the coronary vessels is currently the "gold standard" technique used in clinical practice to establish the coronary anatomy, and remains the cornerstone for the decision making process of choosing medical therapy versus percutaneous or surgical revasculariza tion. Visual assessment of coronary luminal stenoses assumes a constant relationship between the degree of stenosis and ischemia as explained by Gould et al, whereby the flow to the myocardium is gradually compromised as the luminal diameter progres sively narrows.
3 Nonetheless, this relationship has been proven to be more complex and visual assessment of coronary luminal stenosis has been shown to poorly correlate with ischemia, particularly for lesions of moderate severity (40%-70% stenosis). 4, 5 Fractional flow reserve (FFR) is based on the relation ship between coronary artery pressure and blood flow. 6 Although this relationship is fairly variable at rest, during maximal hyperemia there is a linear relationship between coronary pressure and flow because myocardial resistance is minimal and therefore constant. 7 FFR is defined as the ratio of maximal achievable blood flow in a coronary artery in the presence of a stenosis to the hypothetical maximal achievable blood flow in that same epicardial artery in the absence of the stenosis. 8 It is calculated during invasive cardiac catheterization by measuring pressure beyond the stenotic lesion. This is most commonly achieved using a guide wire with a pressuresensing transducer at its distal end, although alternative methods such as optical interferometric sensors can also be employed. After induction of maximal hyperemia using an epicardial as well as a microvascular vasodilating agent (often nitroglycerine and adenosine), the pressure gradient across the lesion is recorded and FFR is calculated as the minimal stable ratio of the mean distal coronary pressure to the mean aortic pressure.
9,10 Pressure reduction of more than 25% at the distal vessel (FFR ,0.75) correlates well with objective myocardial ischemia, whereas relative pressure reductions in the distal vessel of less than 20% (FFR .0.80) rarely do.
11
There is a wealth of data demonstrating the superiority of FFRguided revascularization and improved eventfree sur vival when compared to standard angiographyguided revas cularization. [12] [13] [14] [15] [16] [17] In a 5year followup of the DEFER study, percutaneous coronary intervention (PCI) of a functionally nonsignificant stenosis, as indicated by an FFR $0.75, was of no benefit from a prognostic or symptomatic point of view. 13 In accordance with the results from the DEFER study, the FAME study identified a benefit for deferring PCI in patients with multivessel disease and functionally nonsignificant lesions (FFR $0.80), with reduced rates of cardiac events at both 1 and 2 years.
9,14 Similar conclusions were drawn in patients with stable CAD in the FAME2 trial. In this trial, FFRguided therapy reduced the need for urgent revascularization in patients with stable CAD and function ally significant lesions. 16 Therefore, the American College of Cardiology Foundation/ American Heart Association/Society for Cardiovascular Angiography and Interventions guideline for PCI has recom mended the use of an FFRguided strategy in patients with stable ischemic heart disease (class IIa recommendation, level of evidence: A). 18 FFRguided strategy carries an even stronger level of recommendation (class Ia recommendation, level of evidence: A) in the 2014 European guidelines on myocardial revascularization.
19 Surprisingly, despite the unequivocally favorable data, invasive FFR is underutilized in clinical practice, as fewer than 10% of coronary revascu larization procedures in the US utilize FFR, perhaps due to its invasive nature, risk of instrumentation, increased pro cedural time, and the use of pharmacologic agents. 20, 21 This underutilization underscores the need for novel noninvasive methods to evaluate both anatomical and functional aspects of coronary stenosis. Such noninvasive anatomic-physiologic testing prior to cardiac catheterization and intervention may improve patients' outcomes and reduce costs.
Non-invasive imaging of CAD and coronary blood flow
Coronary computed tomography angiography (CTA) has been increasingly used in clinical practice to detect CAD. It is estimated that 2.3 million coronary CTA examinations are performed annually in the US alone. 22 The diagnostic accuracy of coronary CTA for identification of CAD has been demonstrated in several studies with a sensitivity and nega tive predictive value (NPV) approaching 99% in individuals without known CAD. 23, 24 Nevertheless, this high sensitivity is offset by a relatively low specificity and positive predictive value (PPV) (64%-83% and 48%-86% respectively). 21, 22 Despite the high resolution anatomical identification of obstructive CAD, coronary CTA, in its conventional appli cation, cannot determine the hemodynamic significance of coronary lesions and frequently overestimates the degree of coronary stenosis. The results from two recently published trials, PROMISE and SCOTHEART, provided evidence that the use of coronary CTA for chest pain evaluation enhanced the diagnostic accuracy and appropriately altered subsequent therapeutic plans when compared to other modalities of noninvasive functional testing. 25, 26 However, coronary CTA increased the rate of referral for ICA and revascularization by up to 50% with little understanding of the ischemiaproducing lesions raising concerns regarding unnecessary ICA and possibly inappropriate revascularization procedures.
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Diagnostic performance of FFR CTA provide functional assessment of CAD by identifying regions of suboptimal coronary flow and wall motion abnormalities, they do not directly visualize coronary lesions and carry a significant false positive and false negative rate. A homo geneous myocardial perfusion scan does not exclude the presence of CAD, especially in the setting of multivessel CAD and balanced ischemia. 29 Positron emission tomo graphy quantification of the transmural extent of myocardial perfusion is still far from ideal, despite the improvement in spatial resolution.
The combination of anatomic and physiologic imaging from a single imaging test can overcome the limitations of predominantly anatomic (eg, conventional cardiac CTA) and functional stress modalities. Although the CT myocardial perfusion imaging hybrid serves this purpose, it is limited by significant radiation exposure and increased cost. 30 Therefore, recent advances in imaging techniques and fluid dynamics have been applied in the calculation of FFR from coronary CTA (FFR CTA ).
Techniques and scientific basis of FFR CTA calculation
Recent advances in computational fluid dynamics and image based modeling now enable the calculation of coronary artery blood flow and pressure under different physiologic conditions from coronary CTA, without the need for hype remia induction, modification of acquisition protocol, or additional radiation exposure. Coronary flow and pressure can be derived both at rest and during simulated maximum hyperemia permitting the ability to calculate FFR CTA across stenotic lesions. The scientific basis for quantifying FFR CTA has been described in detail by Taylor et al; 31 it is based on the generation of physiologic models of coronary blood flow.
The principal element for the generation of a reliable and precise model of human coronary blood flow is accurate threedimensional anatomic imaging of the aorta and the coro nary circulation. In addition, computation of patientspecific coronary velocity and pressure under different physio logic conditions is feasible through mathematical methods to solve the governing equations of fluid dynamics utilizing basic concepts. [32] [33] [34] The first concept is the calculation of total resting coronary blood flow relative to myocardial mass quantified on coronary CTA. The baseline coronary blood flow at rest is proportional to the oxygen demands of the subtended myo cardium. The second concept is that the resistance of the micro vasculature bed is inversely related to the size of the supplying vessel. [35] [36] [37] The third concept is that the microvasculature has a predictable vasodilator response to adenosine. 38 The governing equations, known as the "NavierStokes equations", are solved to compute coronary blood flow and pressure. Computation of millions of equations simultane ously, and repetition of the process for thousands of time intervals in a single cardiac cycle is required to compute a realistic patientspecific model of the coronary circulation. 39 The numerical methods for solving fluid dynamics problems are known as computational fluid dynamics. 31 In addition to solving the governing equations, it is neces sary to define the domain of interest and boundary conditions that interface the modeled domain to the remainder of the circulation in order to construct a precise patientspecific blood flow model. The domain of interest is the segment where the blood is flowing (the lumen), and the relevant boundaries, extracted from cardiac CTA data, including the lateral surface, the inlet boundary (the aortic root), and the outlet boundaries of the ascending aorta and the coronary arteries. Boundary conditions are mathematical relationships between the variables of interest (eg, flow and pressure; see Figure 1 ). The final step in constructing a realistic model of coronary flow requires coupling of lumped parameter models of the heart, systemic circulation, and coronary circulation to a patientspecific model of the root of the aorta along with the coronary tree extracted from cardiac CTA data. Finally, maximum hyperemia is simulated by modeling the effect of adenosine on reducing the peripheral microvascular myocar dial resistance downstream of the coronary artery stenosis to compute FFR CTA . It has been shown that in coronary arteries with normal coronary flow reserve, total coronary resistance at maximum hyperemia drops to a quarter of the resting value with intravenous administration of 140 mg/kg/min of adenosine. 38 FFR CTA is then computed as the ratio of the mean hyperemic pressure downstream of the coronary stenosis to the mean hyperemic pressure in the aorta.
Diagnostic performance of FFR CTA in correlation with invasive FFR
Emerging data suggest that noninvasive calculation of lesionspecific FFR, as described in "Noninvasive imaging of CAD and coronary blood flow" section, is feasible using coronary CTA with high diagnostic performance. Using invasive FFR as a reference, the diagnostic accuracy of FFR CTA has been tested in three clinical trials. [40] [41] [42] In the DISCOVERFLOW study, 103 patients with known or sus pected CAD underwent coronary CTA in four international centers. Obstructive CAD was defined as a stenosis $50% on coronary CTA and lesionspecific ischemia was defined as FFR or FFR CTA #0. 8 40 The above findings were subsequently reproduced in a larger cohort, the DeFACTO study. 41 Similar to the DISCOVERFLOW study, 252 stable patients with known or suspected CAD in 17 international centers were evaluated with cardiac CTA, FFR CTA , and invasive FFR. Obstructive CAD was defined as a stenosis $50% and ischemia was defined as FFR or FFR CTA #0.8. FFR CTA demonstrated supe riority over coronary CTA in ischemia determination. The DeFACTO study's prespecified primary outcome goal was to demonstrate a perpatient diagnostic accuracy for FFR CTA of .70% at the lower 95% confidence interval (CI) border of certainty. In perpatient analysis, sensitivity, specificity, PPV, and NPV were 90%, 54%, 67%, and 84% with FFR CTA compared to 84%, 42%, 61%, and 72% with coronary CTA respectively. Although the study failed to meet its primary endpoint, FFR CTA demonstrated improved accuracy for the diagnosis of ischemia compared to coronary CTA alone; 73% (95% CI 67%-78%) for FFR CTA versus 64% (95% CI 58%-70%) for coronary CTA.
The more recent HeartFlow NXT trial further assessed FFR CTA in 254 patients and generated improved diagnostic accuracy (perpatient accuracy 81%; 95% CI: 76%-85%). 42 Improving the diagnostic accuracy of FFR CTA in the HeartFlow NXT trial when compared to earlier trials, namely, DISCOVER FLOW and DeFACTO, reflects the substantial refinement in FFR CTA technology and physiologic modeling. Subsequently, FFR CTA (HeartFlow Inc, Redwood City, CA, USA) has gained US Food and Drug Administration approval as a class II Coronary Physiologic Simulation Software Device.
The clinical outcomes and resource utilization of FFR CTA guided strategy was recently assessed in the PLATFORM trial. 43 Fivehundred and eightyfour patients with suspected CAD were enrolled in this trial from eleven European cen ters and were assigned to receive "usual testing" or FFR CTA . The primary outcome was the percentage of patients with no evidence of obstructive CAD on ICA. Among patients with a planned ICA, no obstructive CAD was found in 12% of the FFR CTA arm and in 73% of the "usual care" arm (risk difference 61%, 95% CI 53%-69%, P,0.0001). Notably, the FFR CTA guided strategy resulted in cancelation of ICA in 61% of the patients. The authors suggested that the FFR CTA guided strategy is a safe and feasible alternative to ICA. 43 In addition to the above studies, two metaanalyses were conducted to assess the diagnostic performance of FFR CTA . 44, 45 The first metaanalysis included a total of 609 patients and 1,050 vessels from the three major multicenter trials (Heart Flow NXT Trial, DISCOVERFLOW study, and DeFACTO study). 44 Using the merged study results, FFR CTA demonstrated a powerful diagnostic accuracy when compared to coronary Figure 1 Mathematical model of blood flow through an idealized LAD stenosis with a reference diameter of 3.5 mm and 60% diameter reduction stenosis. Notes: A constant pressure (P a =90 mm Hg) is applied at the inlet boundary, and a constant resistance, R micro , is prescribed at the outlet boundary to simulate the downstream microcirculatory resistance. The velocity is set at zero along the luminal boundary. R micro is set at 120,000 dynes.s.cm −2 to model baseline conditions with a flow rate of 1 cc.s −1 and is reduced by a factor of 4.5 to 26,664.4 dynes.s.cm −2 to model hyperemic conditions. Hyperemic flow increases to 3.6 cc.s CT at perpatient and pervessel analyses. The second meta analysis included five studies of high methodological quality; it concluded that FFR CTA exhibited a good degree of diagnos tic accuracy for the detection of ischemiacausing stenosis, when applying FFR as a standard reference. 45 These findings remained consistent regardless of whether the diagnostic accu racy of FFR CTA was examined at a perpatient and pervessel or perlesion level using the threshold FFR value of #0.80.
Clinical effectiveness and economic implications
FFR CTA is a novel noninvasive technology that offers both anatomical and functional assessment of major epicardial coronary arteries. As described above, the computation of FFR from coronary CTA is based on fluid dynamics and physiologic models without the need for image acquisition modification, additional radiation, administration of addi tional contrast or hyperemiainducing medications including adenosine. Furthermore, the accuracy of the FFR CTA to identify ischemiarelated lesions is superior to traditional functional stress testing as it provides precise anatomical identification of ischemiarelated lesions that would otherwise be difficult to identify using other noninvasive modalities.
Similar to invasive FFRguided management strategy, the use of FFR CTA has been shown to improve patient outcome and reduce health care costs. 46, 47 A simple cost analysis simulation was performed in 96 patients from the DISCOVERFLOW study to determine the health care cost under various manage ment scenarios. The projected initial management costs were lowest for the coronary CTAFFR CTA ICA strategy (US$7,674) and highest for ICAvisual assessment strategy (US$10,702). The use of FFR CTA to select patients for ICA and revascular ization would result in 30% lower costs and 12% fewer events at 1 year compared to the most commonly used ICAvisual assessment strategy. 46 Similar results were achieved when a health care cost analysis was conducted on patients from the HeartFlow NXT trial. 47 It was concluded that the use of the FFR CTA strategy to select patients for revascularization would result in 32% lower costs and 19% fewer cardiac events in 1 year, compared with the ICAvisual assessment strategy. 47 
Limitations of FFR CTA
FFR CTA is emerging as an attractive alternative to invasive FFR. There are, however, several challenges that need to be overcome before FFR CTA can be translated into routine clinical practice. First, the technique is limited by the same factors that limit the standard coronary CTA namely: calcifications, tachycardia, motion, and misregistration artifacts. These limitations have become particularly important since pre cise anatomic modeling is an essential step to create an accurate model and to compute a reliable FFR CTA. Similarly, adherence to robust acquisition protocols is important for exact definition of patientspecific boundary conditions. Additionally, the relationships relating myocardial mass to coronary blood flow and resistance to vessel size are prere quisites for generating a patientspecific physiologic model. It is, however, well known that these relationships are highly variable between patients. 31 Furthermore, FFR CTA computation assumes a predictable vasodilatation response to adenosine administration, an assumption which is debatable. 48 Another important limitation is that there are no published data for FFR CTA in more complex anatomy such as the evaluation of coronary artery bypass grafts or for instent restenosis. Finally, the process of FFR CTA calculation is time consuming as it takes several hours per exam using specialized software on a highperformance computing platform. An improvement in automation processing time in the future may help in utilizing FFR CTA as a desirable assessment tool for daytoday clinical practice, although the modeling time may not be a significant limitation in clinical practice in the context of stable CAD.
Conclusion
FFR CTA is a novel noninvasive technology that offers both anatomical and functional assessment of major epicardial coronary arteries. Similar to an invasive FFRguided manage ment strategy, the use of FFR CTA has been shown to improve patients' outcomes and reduce health care costs. FFR CTA is emerging as an attractive alternative to invasive FFR for lowintermediate risk patients. There are, however, several challenges that need to be overcome before FFR CTA can be incorporated into routine clinical practice.
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